Statements (67)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:drug
|
gptkbp:bfsLayer |
4
|
gptkbp:bfsParent |
gptkb:Shire_plc
gptkb:Quillivant_XR gptkb:Concerta gptkb:Shire_Pharmaceuticals |
gptkbp:appointed_by |
oral route
|
gptkbp:approves |
gptkb:1996
|
gptkbp:can_lead_to |
mood swings
|
gptkbp:caused_by |
gptkb:software
dizziness fatigue withdrawal symptoms nervousness stomach pain headaches |
gptkbp:contains |
gptkb:amphetamine
gptkb:dextroamphetamine |
gptkbp:enhances |
cognitive performance
|
gptkbp:formulation |
extended-release
immediate-release |
https://www.w3.org/2000/01/rdf-schema#label |
Adderall
|
gptkbp:increased |
blood pressure
|
gptkbp:ingredients |
psychiatrists
primary care physicians C9 H13 N |
gptkbp:interacts_with |
antidepressants
MAO inhibitors blood pressure medications |
gptkbp:is_associated_with |
euphoria
improved focus increased energy potential for abuse |
gptkbp:is_atype_of |
N06 B A03
|
gptkbp:is_available_in |
various strengths
|
gptkbp:is_available_on |
oral tablet
extended-release capsule |
gptkbp:is_considered |
a Schedule II drug
effective for many patients |
gptkbp:is_often_associated_with |
gptkb:psychologist
|
gptkbp:is_often_used_in |
to enhance academic performance
for recreational purposes to lose weight |
gptkbp:is_part_of |
comprehensive treatment plan
treatment regimen for ADHD |
gptkbp:is_subject_to |
regulatory scrutiny
drug testing |
gptkbp:is_used_by |
gptkb:Person
adults |
gptkbp:is_used_for |
treatment of ADHD
treatment of narcolepsy |
gptkbp:legal_issue |
controlled substance
|
gptkbp:manufacturer |
gptkb:Shire_Pharmaceuticals
|
gptkbp:marketed_as |
various brand names
|
gptkbp:requires |
gptkb:theorem
|
gptkbp:side_effect |
anxiety
insomnia dry mouth increased heart rate loss of appetite |
gptkbp:suitable_for |
pregnant women
nursing mothers patients with glaucoma patients with hyperthyroidism patients with a history of substance abuse patients with heart problems |
gptkbp:type_of |
300-62-9
|